Plasma p-tau217 or p-tau181 has the potential to discriminate AD from FTLD syndromes (Thijssen et al., 2021), but whether p-tau or t-tau levels are low or high among different FTLD subtypes remains unclear. The gene discussed is MAPT; the disease is Alzheimer disease.